Western Securities Co.Ltd(002673) (hereinafter referred to as ” Western Securities Co.Ltd(002673) ” or “sponsor”) as a sponsor of Sansure Biotech Inc(688289) (hereinafter referred to as ” Sansure Biotech Inc(688289) ” or “company”) for initial public offering of shares and listing on the science and innovation board, According to the requirements of laws, regulations and normative documents such as the Listing Rules of Shanghai Stock Exchange on the science and Innovation Board (revised in December 2020), the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (revised in 2022), and the measures for the continuous supervision of listed companies on the science and Innovation Board (Trial), the deposit and use of raised funds in Sansure Biotech Inc(688289) 2021 were carefully verified, The verification is as follows:
1、 Basic information of funds raised by initial public offering
(I) actual amount of raised funds and receipt of funds
According to the reply on Approving the registration of Sansure Biotech Inc(688289) initial public offering (zjxk [2020] No. 1580) issued by China Securities Regulatory Commission on July 28, 2020, the company was approved to issue 40000000 ordinary shares to the public, with an issue price of 50.48 yuan per share and a total raised capital of 2019.2 million yuan; After deducting the underwriting and recommendation fees, issuance registration fees and other transaction expenses totaling 149930200 yuan (excluding the amount of value-added tax), the net amount of raised funds is 1869269800 yuan. All the above funds have been in place, which has been verified by Zhongshen Zhonghuan Certified Public Accountants (special general partnership) and issued the capital verification report (Zhonghuan Yan Zi (2020) No. 110009) (hereinafter referred to as the “capital verification report”) on August 25, 2020. All the raised funds have been deposited in the special account for raised funds opened with the approval of the board of directors of the company. The company has signed a tripartite supervision agreement for raised funds with the sponsor and the commercial bank storing the raised funds. For details, see the company’s disclosure on the website of Shanghai Stock Exchange (www.sse. Com. CN.) on August 27, 2020 Announcement on the listing of Sansure Biotech Inc(688289) initial public offering of shares on the science and innovation board.
(II) use and balance of raised funds
As of December 31, 2021, the use of the company’s raised funds is as follows:
Project amount (yuan)
The net amount of actually raised funds is 186926981132
Less: accumulated use amount of raised funds (including replacement advance investment amount) 50384704665
Including: 10347947437 of the production base project of precision intelligent molecular diagnosis system
Marketing network and information upgrading construction project 446574475
R & D upgrading project 590182753
Permanent supplementary working capital 39000000000
Plus: net interest income of raised funds after deducting handling charges 840179837
Less: cash management amount using raised funds: 515000000000
Plus: the amount of recovered raised funds for cash management is 425000000000
Plus: income from cash management with raised funds 3673710186
As of December 31, 2021, the balance of raised funds should be 51056166490
2、 Deposit and management of raised funds
(I) management of raised funds
In order to standardize the management and use of raised funds, improve the efficiency and efficiency of fund use, and protect the rights and interests of investors, In accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (revised in 2022), the Listing Rules of science and Innovation Board of Shanghai Stock Exchange (revised in December 2020), the measures for the continuous supervision of science and Innovation Board Listed Companies (Trial Implementation) and other relevant laws, regulations and normative documents, Combined with the actual situation of the company, the management system of raised funds is formulated. In accordance with the provisions of the raised funds management system, the company adopts a special account storage system for the raised funds and strictly performs the use approval procedures, so as to supervise the management and use of the raised funds and ensure that the special funds are used for special purposes.
In August 2020, the company signed the tripartite supervision agreement on raised funds (hereinafter referred to as the “supervision agreement”) with the sponsor, China Everbright Bank Company Limited Co.Ltd(601818) Changsha branch, China Construction Bank Corporation(601939) Changsha Huaxing sub branch, Shanghai Pudong Development Bank Co.Ltd(600000) Changsha branch and Hunan Sanxiang Bank Co., Ltd. On October 29, 2020, the proposal of Sansure Biotech Inc(688289) on the establishment of a special account for raised funds by a wholly-owned subsidiary was deliberated and approved at the fourth meeting of the first board of directors in 2020. On November 17, 2020, the company signed the four party supervision agreement for raised funds (hereinafter referred to as the “supervision agreement”) with the recommendation institution and Industrial Bank Co.Ltd(601166) Shanghai Minhang sub branch and Shengxiang (Shanghai) Gene Technology Co., Ltd. On January 22, 2021, the company signed the tripartite supervision agreement on raised funds (hereinafter collectively referred to as the “supervision agreement”) with the sponsor Western Securities Co.Ltd(002673) and Bank Of Changsha Co.Ltd(601577) Dongcheng sub branch. The deposit and management of the company’s raised funds in 2021 shall be carried out in strict accordance with the above supervision agreement.
(II) deposit of raised funds in special account
As of December 31, 2021, the company has 6 special accounts for raised funds, and the deposits of raised funds are as follows:
Company name deposit bank account balance (yuan) deposit method
Sansure Biotech Inc(688289) Technology China China Everbright Bank Company Limited Co.Ltd(601818) shares
Changsha Xingsha 78730188000182639451876448 current sub branch of Co., Ltd
Sansure Biotech Inc(688289) Technology China China Construction Bank Corporation(601939) shares
Co., Ltd. Changsha Huaxing 430501763636 China High-Speed Railway Technology Co.Ltd(000008) 231467365967 current sub branch business department
Sansure Biotech Inc(688289) Technology Shanghai Pudong Development Bank 661800788010 Shenzhen Fountain Corporation(000005) 0827947863 current Co., Ltd. Changsha sub account:
Biological medicine sub branch 661800788010 China Vanke Co.Ltd(000002) 3417144972112 current account
Sansure Biotech Inc(688289) Technology Hunan Sanxiang Bank Co., Ltd. 00700101 China Vanke Co.Ltd(000002) 96911903.79 current Co., Ltd
Sansure Biotech Inc(688289) technology Bank Of Changsha Co.Ltd(601577) Co., Ltd. 8 Shenzhen Guohua Network Security Technology Co.Ltd(000004) 7142 China Baoan Group Co.Ltd(000009) 31780075259 current Co., Ltd. Dongcheng sub branch Shengxiang (Shanghai) Industrial Bank Co.Ltd(601166) Co., Ltd
Gene Technology Co., Ltd. Shanghai Minhang sub branch 216110100408903182738462 current company
Total 51056166490
In order to improve the use efficiency of raised funds, the company purchased principal guaranteed financial products or structured deposits from some temporarily idle raised funds. As of December 31, 2021, the relevant balance is as follows:
Type of products purchased by the trustee (yuan per day)
China China Everbright Bank Company Limited Co.Ltd(601818) Co., Ltd. 2021 linked exchange rate corporate structured deposit 170000 China Vanke Co.Ltd(000002) 02112-9 Co., Ltd. Changsha branch customized phase XII product 174
Huatai Securities Co.Ltd(601688) Co., Ltd. Huatai Securities Co.Ltd(601688) Huanyi No. 21002 (commodity 10000000000, 202110-29 company currency basket) income certificate
Huatai Securities Co.Ltd(601688) Co., Ltd. Huatai Securities Co.Ltd(601688) Juyi No
Company No. 21390 (crude oil futures) income certificate 200000 China Vanke Co.Ltd(000002) 02112-28 (principal guaranteed income certificate)
Shanghai Pudong Development Bank Co.Ltd(600000) Changsha biolido company stable profit 21jg6497 (phase 3)
Pharmaceutical sub branch monthly bullish outlets (exclusive) RMB 20000000000 corporate structured deposit 202111-12
Shanghai Pudong Development Bank Co.Ltd(600000) Changsha biological Pudong Development Ningbo Branch exclusive unit large deposit certificate for phase 0031 of 30000 China Vanke Co.Ltd(000002) 021-5-12 pharmaceutical sub branch in 2021
China China Construction Bank Corporation(601939) Hunan unit structured deposit 2021 issue 26200000 China Vanke Co.Ltd(000002) 02112-30 provincial branch
Total 900000000000
3、 Actual use of raised funds in 2021
(I) comparison table of use of raised funds
As of December 31, 2021, refer to “Annex 1 comparison table of the use of raised funds in 2021” for the use of funds of raised investment projects.
(II) early investment and replacement of raised investment projects
The company held the first meeting of the first board of directors in 2021 and the first meeting of the first board of supervisors in 2021 on January 28, 2021, deliberated and approved the proposal on using raised funds to replace self raised funds invested in projects invested by raised funds in advance and paying issuance expenses, and agreed to use raised funds to replace self raised funds invested in projects invested by raised funds in advance and paid issuance expenses, totaling 3072777403 yuan, The independent directors of the company expressed clear consent and performed the necessary legal procedures. Zhongshen Zhonghuan Certified Public Accountants (special general partnership) issued the verification report of Sansure Biotech Inc(688289) replacing self raised funds invested in projects raised in advance and paying issuance expenses with raised funds (Zhonghuan zhuanzi (2021) No. 1100002). The recommendation institution has issued Western Securities Co.Ltd(002673) verification opinions on Sansure Biotech Inc(688289) raised funds replacing self raised funds invested in advance and paid issuance expenses on February 1, 2021.
According to the relevant provisions of the Listing Rules of Shanghai Stock Exchange on the science and Innovation Board (revised in December 2020), the company has used the net raised funds of 3072777403 yuan to replace the self raised funds invested in advance. The company has transferred the raised funds of 3072777403 yuan to the bank account of the company’s own funds, and completed the replacement of the early investment of the raised funds investment project. The replacement does not change the purpose of the company’s raised funds in a disguised manner, and the replacement time is less than 6 months from the arrival time of the raised funds, which meets the regulatory requirements.
(III) temporary replenishment of working capital with idle raised funds
As of December 31, 2021, the company has not temporarily supplemented the current flow with idle raised funds in this year
(IV) cash management of idle raised funds and investment in related products
In order to improve the use efficiency of funds and make rational use of idle raised funds, the company held the third meeting of the first board of directors in 2020 and the second meeting of the first board of supervisors in 2020 on September 16, 2020, deliberated and approved the Sansure Biotech Inc(688289) proposal on using some temporarily idle raised funds for cash management, and agreed to use temporarily idle raised funds with a total of no more than RMB 13000000000 for cash management, For the purchase of principal guaranteed financial products or structured deposits with high security and good liquidity, the resolution is valid for 12 months from the date of deliberation and approval by the board of directors of the company, and can be used on a rolling basis within the above-mentioned period. The company held the first board meeting on September 15, 2021
